https://scholars.lib.ntu.edu.tw/handle/123456789/570831
標題: | Epidemiology and management of HCV Infection | 作者: | HUNG-CHIH YANG | 公開日期: | 2020 | 出版社: | Hong Kong Academy of Medicine Press | 卷: | 30 | 期: | 1 | 起(迄)頁: | 145-149 | 來源出版物: | East Asian Archives of Psychiatry | 摘要: | Hepatitis C virus (HCV) infection is an important issue of global public health. Approximately 180 million individuals have been infected by HCV. Estimated by WHO in 2015, around 71 million patients were chronically infected by HCV, and most of them lived in Asia. The incidence of chronic hepatitis C (CHC) was about 1%. Hepatitis C is transmitted primarily via body fluid or blood. Development of all-oral direct antiviral agents (DAAs) has caused a paradigm shift for treatment of CHC. In the past, the standard care of CHC was the combination of pegylated interferon plus ribavirin, which had a higher risk of adverse effects and less tolerable, although it was quite effective. DAAs are more effective and safer, so are more welcome and suitable for treatment of CHC patients. In 2016, WHA advocated "to eliminate viral hepatitis as a public health threat by 2030". Taiwan's government has set a more ambitious goal, aiming to eliminate hepatitis C by 2025. This achievement will be a milestone for management and prevention of CHC, making human society free from the threat of HCV infection forever. ? 2020 Hong Kong Academy of Medicine Press. All rights reserved. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85096200245&doi=10.6314%2fJIMT.202006_31%283%29.02&partnerID=40&md5=98b17231ac6092b114032a0337df632c https://scholars.lib.ntu.edu.tw/handle/123456789/570831 |
ISSN: | 2078-9947 | DOI: | 10.6314/JIMT.202006_31(3).02 | SDG/關鍵字: | Article; hepatitis C; Hepatitis C virus; human; infection prevention |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。